Approval · Notice of Compliance 28209 · 2022
DYMISTA: Notice of Compliance 28209
Issued May 18, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28209
- Date
- May 18, 2022
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of indication, Updates to the Patient Medication Information, Migrate Product Monograph to 2020 format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DYMISTA | Not yet assigned | — |
Medicinal ingredients
- FLUTICASONE PROPIONATE 0.05 MG per ACT
- AZELASTINE HYDROCHLORIDE 0.137 MG per ACT